The FGF21 analogue LY2405319 was subcutaneously administered for 28 days to patients with obesity and T2DM, resulting in attenuated dyslipidaemia, reduced body weight and plasma insulin, and increased adiponectin levels [94]. Here, ADIPOQ is linked to type 2 diabetes mellitus.